Patents by Inventor Riad Kharrat

Riad Kharrat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Maurocalcine, analogues thereof and their therapeutical uses
    Patent number: 7319089
    Abstract: Maurocalcine, a novel toxin isolated from the venom of the Tunisian chactidae scorpion Scorpio maurus palmatus, has the amino acid sequence GDCLPHLKLCKENKDCCSKKCKRRGTNIEKRCR (SEQ. ID. No. 1). It potently and reversibly modifies channel gating behaviour of type 1 ryanodine receptor (RyR1) by inducing prominent subconductance behavior. Maurocalcine and its bioactive structural analogues—preferably those containing the KKCKRR motif corresponding to part of the II-III loop of the alpha1S subunit of the voltage-dependent skeletal muscle calcium channel dihydropyridine receptor—appear to possess a therapeutic potential, notably as candidate immuno-suppressive drugs, and for the treatment of pathologies in humans that may involve a dysfunction of calcium channels.
    Type: Grant
    Filed: March 5, 2001
    Date of Patent: January 15, 2008
    Assignee: Cellpep Pharma Inc.
    Inventors: Riad Kharrat, Kamel Mabrouk, Mohammed El-Ayeb, Hervé Rochat, Jean-Marc Sabatier
  • Maurocalcine, analogues thereof and their therapeutical uses
    Publication number: 20030158108
    Abstract: Maurocalcine, a novel toxin isolated from the venom of the Tunisian chactidae scorpion Scorpio maurus palmatus, has the amino acid sequence GDCLPHLKLCKENKDCCSKKCKRRGTNIEKRCR (SEQ. ID. No. 1). It potently and reversibly modifies channel gating behaviour of type 1 ryanodine receptor (RyR1) by inducing prominent subconductance behavior. Maurocalcine and its bioactive structural analogues—preferably those containing the KKCKRR motif corresponding to part of the II-III loop of the alpha1S subunit of the voltage-dependent skeletal muscle calcium channel dihydropyridine receptor—appear to possess a therapeutic potential, notably as candidate immuno-suppressive drugs, and for the treatment of pathologies in humans that may involve a dysfunction of calcium channels.
    Type: Application
    Filed: November 14, 2002
    Publication date: August 21, 2003
    Inventors: Riad Kharrat, Kamel Mabrouk, Mohammed El-Ayeb, Herve Rochat, Jean-Marc Sabatier